GSE172494 nicotinamide 3 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE172494_nicotinamide_3_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE172494_nicotinamide_3_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE172494_nicotinamide_3_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE172494_nicotinamide_3_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

family with sequence similarity 30 member A

Gene

H19 imprinted maternally expressed transcript

Gene

MT-CO2 pseudogene 12

Gene

long intergenic non-protein coding RNA 2593

Gene

CDH13 antisense RNA 2

Gene

FSHD region gene 1 family member C, pseudogene

Gene

H3 clustered histone 10

Gene

uncharacterized LOC339260

Gene

deleted in lymphocytic leukemia 2

Gene

NIPBL divergent transcript

  • Gene

    family with sequence similarity 30 member A


  • Gene

    H19 imprinted maternally expressed transcript


  • Gene

    MT-CO2 pseudogene 12


  • Gene

    long intergenic non-protein coding RNA 2593


  • Gene

    CDH13 antisense RNA 2


  • Gene

    FSHD region gene 1 family member C, pseudogene


  • Gene

    H3 clustered histone 10


  • Gene

    uncharacterized LOC339260


  • Gene

    deleted in lymphocytic leukemia 2


  • Gene

    NIPBL divergent transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.